A Phase 3 interventional study of Rosiglitazone and Sulfonylurea in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 447 sites in 25 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-23.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.
Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one has the largest enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2001, is one of 21 in phase 3, and was the 30th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,447 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 149 across the 51 interventional studies. Of the 50 that completed or were terminated, 15 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 52 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 133 finished, 46 (35%) have results posted.
Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2001, is one of 28 in phase 3, and was the 29th registered.
GlaxoSmithKline’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 136 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background glucose lowering therapy. Patients inadequately controlled on background metformin will be randomised to receive, in addition to metformin, either rosiglitazone or a sulfonylurea(glibenclamide, gliclazide or glimepiride) in a ratio of 1:1. Patients inadequately controlled on background SU will be randomised to receive, in addition to SU, either rosiglitazone or metformin in a ratio of 1:1. Equal numbers of patients receiving background metformin and SU at entry will be entered into the study.
A RECORD follow-up study is being performed to monitor the incidence of cancer and bone fractures in RECORD patients for a period of 4 years after the end of the main RECORD study (2008 - 2012).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
Drug: Rosiglitazone · Drug: Metformin
Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
Drug: Rosiglitazone · Drug: Sulfonylurea
Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.
Drug: Sulfonylurea · Drug: Metformin
Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
Drug: Sulfonylurea · Drug: Metformin
Rosiglitazone maximum 8 mg per day
Drug pages: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea
Sulfonylurea (SU) maximum permitted daily dose
Metformin maximum permitted daily dose .
Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events
The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded.
Time frame: Baseline through End of Study (up to 7.5 years)
Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause
All deaths identified during the original record study and discovered after the re-adjudication efforts began were included.
Time frame: Baseline through End of Study (up to 7.5 years)
Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions
IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin.
Time frame: Baseline through End of Study (up to 7.5 years)
Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions
Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.
Time frame: Baseline through End of Study (up to 7.5 years)
Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions
The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as "unknown deaths," but were counted as CV deaths for the analysis of this endpoint.
Time frame: Baseline through End of Study (up to 7.5 years)
Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions
The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths.
Time frame: Baseline through End of Study (up to 7.5 years)
Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions
The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme \>= 2x the ULN or CK \> 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI.
Time frame: Baseline through End of Study (up to 7.5 years)
Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions
The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.
Time frame: Baseline through End of Study (up to 7.5 years)
Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions
Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke.
Time frame: Baseline through End of Study (up to 7.5 years)
Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions
The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.
Time frame: Baseline through End of Study (up to 7.5 years)
Number of Participants With Cardiovascular Events and All-cause Deaths
Composites of participants with first cardiovascular (CV) hospitalisations and CV death or all-cause death and individual first events of acute myocardial infarction (MI) , stroke, congestive heart failure (CHF), CV death, and all-cause death.
Time frame: Baseline through End of Study (up to 7.5 years)
Total Number of Cardiovascular Hospitalisations and Cardiovascular Deaths
The total number of events for individual components of cardiovascular (CV) hospitalisations and cardiovascular deaths were recorded. MI, myocardial infarction.
Time frame: Baseline through End of Study (up to 7.5 years)
Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum
Participants with first cardiovascular death (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) were recorded by study stratum.
Time frame: Baseline through End of Study (up to 7.5 years)
Number of Participants With CV/Microvascular Events
The number of participants with first cardiovascular or microvascular events (renal, foot, eye) were recorded.
Time frame: Baseline through End of Study (up to 7.5 years)
Number of Participants With Glycaemic Failure Events
Failure of glycaemic control was defined as two consecutive HbA1c values of ≥8.5 percent, or HbA1c ≥8.5percent at a single visit, after which the subject was either moved to the post-randomised treatment phase or triple therapy was started.
Time frame: Baseline through to end of randomised dual therapy
Number of Participants With Addition of Third Oral Agent/Switch to Insulin
The number of participants with addition of a third oral agent or switch to insulin from randomised dual combination treatment were recorded.
Time frame: Baseline through End of Study (up to 7.5 years)
The Number of Participants Starting Insulin at Any Time During the Study
The number of participants starting insulin at any time during the study was recorded.
Time frame: Baseline through End of Study (up to 7.5 years)
Model Adjusted Change From Baseline in HbA1c at Month 60
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in HbA1c was calculated as the value at Month 60 minus the Baseline value.
Time frame: Baseline and Month 60 of randomised dual therapy treatment period
Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in fasting plasma glucose was calculated as the value at Month 60 minus the Baseline value.
Time frame: Baseline to Month 60 of the randomised dual therapy treatment period
Model Adjusted Mean Change From Baseline in Insulin and Pro-insulin at Month 60
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in insulin and pro-insulin was calculated as the value at Month 60 minus the Baseline value.
Time frame: Baseline to Month 60 of the randomised dual therapy treatment period
Number of HbA1c and Fasting Plasma Glucose (FPG) Responders at Month 60
Number of responders, i.e., participants meeting glycaemic targets (HbA1c less than or equal to 7 percent, FPG less than or equal to 7 mmol/L)
Time frame: Baseline to Month 60 of the randomised dual therapy treatment period
Model Adjusted Ratio to Baseline (Expressed as a Percentage) Homeostasis Model Assessment (HOMA) Beta Cell Function and Insulin Sensitivity at Month 60
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in HOMA beta-cell function and insulin sensitivity was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC), Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Triglycerides, and Free Fatty Acids (FFAs) at Month 60
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC, LDL cholesterol, HDL cholesterol, triglycerides, and FFAs was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC):High-density Lipoprotein (HDL) Cholesterol and Low-density Lipoprotein (LDL) Cholesterol:HDL Cholesterol Ratios at Month 60
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC:HDL cholesterol and LDL cholesterol:HDL cholesterol was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
Time frame: Baseline to Month 60 of the randomised dual therapy treatment period
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in Apo-B was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
Time frame: Baseline to Month 60 of the randomised dual therapy treatment period
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in urinary albumin creatinine ratio was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Model Adjusted Change From Baseline in Body Weight at Month 60
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in body weight was calculated as the value at Month 60 minus the Baseline value.
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in alanine aminotransferase was calculated as the value at Month 60 minus the Baseline value.
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Model Adjusted Change From Baseline in Waist Circumference at Month 60
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in waist circumference was calculated as the value at Month 60 minus the Baseline value.
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Model Adjusted Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 60
Model adjusted (adjusted for any imbalances in the baseline values between within treatment groups) change from baseline in SBP and DBP was calculated as the value at Month 60 minus the Baseline value.
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in C-Reactive Protein was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 60
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in fibrinogen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in plasminogen activator inhibitor-1 (PAI-1) antigen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase
Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Main Study + Observational Follow-up Combined
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Observational Follow-up
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Main Study + Observational Follow-up Combined
The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Observational Follow-up
The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Number of Participants Who Died Due to the Indicated Cancer-related Event: Main Study + Observational Follow-up Combined
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants Who Died Due to the Indicated Cancer-related Event: Observational Follow-up
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Number of Participants With a Bone Fracture Event - Overall and by Gender: Main Study and Observational Follow-up Combined
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants With a Bone Fracture Event - Overall and by Gender: Observational Follow-up
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Main Study + Observational Follow-up Combined
The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Observational Follow-up
The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants With the Indicated Bone Fracture by Fracture Site: Main Study + Observational Follow-up Combined
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants With the Indicated Bone Fracture by Fracture Site: Observational Follow-up
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Number of Participants With Potentially High Morbidity Fractures: Main Study + Observational Follow-up Combined
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants With Potentially High Morbidity Fracture Events and Non-high Morbidity Fracture Events, in Participants With Prior Hand/Upper Arm/Foot Fractures (H/UA/FF): Main Study + Observational Follow-up Combined
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants With Bone Fracture Events of the Indicated Cause: Main Study + Observational Follow-up Combined
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Participants With Bone Fracture Events of the Indicated Cause: Observational Follow-up
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."
Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Number of Bone Fracture Events With the Indicated Outcome: Main Study + Observational Follow-up Combined
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."
Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Number of Bone Fracture Events With the Indicated Outcome: Observational Follow-up
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."
Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
The RECORD study ran from April 2001 through December 2008. Results are presented in the non-re-adjudicated outcome measures (OMs). An independent patient-level re-adjudication of mortality, non-fatal myocardial infarction, and non-fatal stroke began on January 2011 and ran through March 2012. The results are presented in the re-adjudicated OMs.
| Milestone | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|---|---|---|---|
| Started | 1117 | 1105 | 1103 | 1122 | 0 | 0 |
| Completed | 939 | 906 | 896 | 892 | 0 | 0 |
| Not completed | 178 | 199 | 207 | 230 | 0 | 0 |
| Withdrew: Death | 57 | 67 | 54 | 72 | 0 | 0 |
| Withdrew: Adverse event | 5 | 8 | 10 | 11 | 0 | 0 |
| Withdrew: Lost to follow-up | 29 | 29 | 25 | 26 | 0 | 0 |
| Withdrew: Withdrawal by subject | 46 | 56 | 72 | 70 | 0 | 0 |
| Withdrew: Moved to survival status follow-up only | 27 | 25 | 32 | 36 | 0 | 0 |
| Withdrew: Participant moved | 3 | 2 | 3 | 3 | 0 | 0 |
| Withdrew: Poor compliance | 3 | 2 | 2 | 1 | 0 | 0 |
| Withdrew: Prohibited glucose lowering medication | 0 | 3 | 0 | 1 | 0 | 0 |
| Withdrew: Site closed | 4 | 4 | 4 | 8 | 0 | 0 |
| Withdrew: Entry criteria violation | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Participant did not take study drug | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Participant completed study at visit 27 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Personal reasons | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Risk of heart failure | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator refused to log temperature | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Reason unspecified | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 1280 | 1250 |
| Completed | 0 | 0 | 0 | 0 | 1131 | 1102 |
| Not completed | 0 | 0 | 0 | 0 | 149 | 148 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 78 | 70 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 25 | 27 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 12 | 12 |
| Withdrew: Entered into another clinical trial | 0 | 0 | 0 | 0 | 18 | 22 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 8 | 8 |
| Withdrew: Site closed early | 0 | 0 | 0 | 0 | 6 | 7 |
| Withdrew: Participant moved | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Unknown; reason not provided | 0 | 0 | 0 | 0 | 1 | 1 |
The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events | 321 | 323 |
Composites of participants with first cardiovascular (CV) hospitalisations and CV death or all-cause death and individual first events of acute myocardial infarction (MI) , stroke, congestive heart failure (CHF), CV death, and all-cause death.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| CV death, acute MI, stroke | 154 | 165 |
| CV death, acute MI, stroke, unstable angina | 171 | 184 |
| CV death, acute MI, stroke, unstable angina, CHF | 204 | 206 |
| All-cause death,acuteMI,stroke,unstable angina,CHF | 251 | 268 |
| Acute MI (fatal or non-fatal) | 64 | 56 |
| Stroke (fatal or non-fatal) | 46 | 63 |
| CHF (fatal or non-fatal) | 61 | 29 |
| Death from CV causes | 60 | 71 |
| Death (all cause) during CV follow-up | 111 | 139 |
| Death (all-cause) including survival status | 136 | 157 |
The total number of events for individual components of cardiovascular (CV) hospitalisations and cardiovascular deaths were recorded. MI, myocardial infarction.
| Number of events | Combined RSG | Combined MET/SU |
|---|---|---|
| CV deaths | 60 | 71 |
| Death due to acute MI | 7 | 10 |
| Death due to heart failure | 10 | 2 |
| Sudden death | 8 | 12 |
| Death due to acute vascular events | 1 | 10 |
| Other CV mortality | 6 | 4 |
| Death of presumed CV cause | 28 | 33 |
| Cardiovascular hospitalisation | 483 | 490 |
| Hospitalisation for acute MI | 66 | 57 |
| Hospitalisation for unstable angina | 28 | 28 |
| Hospitalisation for congestive heart failure | 69 | 36 |
| Hospitalisation for stroke | 51 | 67 |
| Hospitalisation for transient ischaemic attack | 10 | 10 |
| Hospitalisation for invasive CV procedure | 99 | 116 |
| Hospitalisation for amputation of extremities | 6 | 23 |
| Other CV hospitalisations | 154 | 153 |
Participants with first cardiovascular death (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) were recorded by study stratum.
| partcipants | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum | 158 | 154 | 163 | 169 |
The number of participants with first cardiovascular or microvascular events (renal, foot, eye) were recorded.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Participants with a CV/Microvascular event | 363 | 385 |
| Participants with any microvascular event | 59 | 78 |
| Participants with any eye event | 42 | 52 |
| Participants with any foot event | 19 | 28 |
| Participants with any renal event | 0 | 0 |
Failure of glycaemic control was defined as two consecutive HbA1c values of ≥8.5 percent, or HbA1c ≥8.5percent at a single visit, after which the subject was either moved to the post-randomised treatment phase or triple therapy was started.
| participants | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Number of Participants With Glycaemic Failure Events | 281 | 451 | 365 | 424 |
The number of participants with addition of a third oral agent or switch to insulin from randomised dual combination treatment were recorded.
| participants | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Participants with an event | 295 | 183 | 344 | 171 |
| First Event - Triple Therapy | 257 | 7 | 296 | 6 |
| First Event - Insulin | 38 | 176 | 49 | 165 |
The number of participants starting insulin at any time during the study was recorded.
| participants | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| The Number of Participants Starting Insulin at Any Time During the Study | 126 | 276 | 168 | 259 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in HbA1c was calculated as the value at Month 60 minus the Baseline value.
| Percent | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Change From Baseline in HbA1c at Month 60 | -0.14 ± 0.035 | 0.17 ± 0.042 | -0.24 ± 0.039 | -0.10 ± 0.039 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in fasting plasma glucose was calculated as the value at Month 60 minus the Baseline value.
| mmol/L (millimoles/Liter) | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60 | -1.38 ± 0.073 | -0.29 ± 0.090 | -2.00 ± 0.085 | -0.94 ± 0.094 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in insulin and pro-insulin was calculated as the value at Month 60 minus the Baseline value.
| picamoles/liter (pmol/L) | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Insulin, Adjusted Change from Baseline | -18.6 ± 1.01 | 3.7 ± 1.77 | -16.9 ± 1.65 | -12.1 ± 1.91 |
| Pro-insulin, Adjusted Change from Baseline | -2.4 ± 0.26 | 4.2 ± 0.43 | -3.2 ± 0.48 | -3.0 ± 0.37 |
Number of responders, i.e., participants meeting glycaemic targets (HbA1c less than or equal to 7 percent, FPG less than or equal to 7 mmol/L)
| participants | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| HbA1c Responders | 265 | 208 | 235 | 180 |
| FPG Responders | 300 | 180 | 257 | 154 |
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in HOMA beta-cell function and insulin sensitivity was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
| percent change | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Beta cell function | 20.54 (16.52 to 24.70) | 19.28 (14.66 to 24.09) | 32.35 (26.55 to 38.41) | 12.43 (7.42 to 17.67) |
| Insulin sensitivity | 42.57 (37.57 to 47.76) | -3.45 (-7.21 to 0.47) | 42.07 (36.39 to 47.98) | 23.90 (19.36 to 28.61) |
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC, LDL cholesterol, HDL cholesterol, triglycerides, and FFAs was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
| percent change | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Total cholesterol | -5.49 (-6.99 to -3.96) | -9.09 (-10.33 to -7.84) | -2.91 (-4.62 to -1.17) | -9.68 (-11.03 to -8.31) |
| HDL-cholesterol | 9.95 (8.44 to 11.49) | 2.57 (1.46 to 3.68) | 7.73 (6.18 to 9.30) | 6.14 (4.88 to 7.42) |
| LDL-cholesterol | -12.70 (-15.03 to -10.30) | -17.68 (-19.70 to -15.61) | -8.99 (-11.42 to -6.49) | -17.80 (-19.93 to -15.61) |
| Triglycerides | -7.97 (-10.72 to -5.15) | -1.95 (-4.73 to 0.91) | -2.68 (-5.69 to 0.43) | -2.50 (-5.21 to 0.28) |
| Free fatty acids | -16.46 (-19.13 to -13.71) | 2.79 (-0.23 to 5.91) | -11.58 (-14.65 to -8.41) | 4.47 (1.23 to 7.81) |
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC:HDL cholesterol and LDL cholesterol:HDL cholesterol was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
| percent change | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Total Cholesterol: HDL Cholesterol Ratio | -14.20 (-15.98 to -12.39) | -11.33 (-12.82 to -9.81) | -9.93 (-11.83 to -7.98) | -15.01 (-16.44 to -13.55) |
| LDL Cholesterol: HDL-Cholesterol Ratio | -20.89 (-23.24 to -18.46) | -20.04 (-22.16 to -17.87) | -15.85 (-18.26 to -13.37) | -22.53 (-24.63 to -20.37) |
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in Apo-B was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
| percent change | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60 | -13.77 (-15.45 to -12.05) | -11.63 (-13.10 to -10.14) | -9.68 (-11.55 to -7.77) | -12.09 (-13.67 to -10.47) |
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in urinary albumin creatinine ratio was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
| percent change | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60 | 8.31 (-0.70 to 18.14) | 15.17 (6.73 to 24.28) | -3.43 (-11.91 to 5.87) | 11.91 (3.10 to 21.46) |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in body weight was calculated as the value at Month 60 minus the Baseline value.
| kilograms | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Change From Baseline in Body Weight at Month 60 | 3.93 ± 0.263 | -0.54 ± 0.192 | 4.72 ± 0.235 | -2.16 ± 0.179 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in alanine aminotransferase was calculated as the value at Month 60 minus the Baseline value.
| U/L (Units/Liter) | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60 | -37.43 (-39.22 to -35.59) | -21.73 (-23.90 to -19.50) | -30.17 (-31.98 to -28.31) | -24.00 (-26.21 to -21.73) |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in waist circumference was calculated as the value at Month 60 minus the Baseline value.
| cm (centimeters) | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Change From Baseline in Waist Circumference at Month 60 | 2.70 ± 0.266 | 0.65 ± 0.214 | 3.00 ± 0.263 | -0.60 ± 0.215 |
Model adjusted (adjusted for any imbalances in the baseline values between within treatment groups) change from baseline in SBP and DBP was calculated as the value at Month 60 minus the Baseline value.
| mmHg (millimeters of mercury) | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| SBP | -1.9 ± 0.54 | -2.2 ± 0.52 | -2.3 ± 0.52 | -0.6 ± 0.53 |
| DBP | -3.6 ± 0.34 | -3.4 ± 0.29 | -3.6 ± 0.31 | -2.3 ± 0.31 |
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in C-Reactive Protein was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
| percent change | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60 | -57.40 (-60.41 to -54.15) | -28.92 (-33.71 to -23.79) | -56.50 (-61.56 to -55.21) | -36.29 (-41.03 to -31.17) |
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in fibrinogen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
| percent change | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 60 | 2.12 (0.54 to 3.72) | 5.74 (4.22 to 7.28) | -0.23 (-1.79 to 1.35) | 3.14 (1.38 to 4.93) |
The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in plasminogen activator inhibitor-1 (PAI-1) antigen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).
| percent change | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU |
|---|---|---|---|---|
| Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60 | -9.85 (-14.42 to -5.02) | 15.01 (9.77 to 20.50) | -7.79 (-12.61 to -2.71) | -0.64 (-5.82 to 4.83) |
All deaths identified during the original record study and discovered after the re-adjudication efforts began were included.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause | 139 | 160 |
IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions | 181 | 188 |
Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions | 186 | 191 |
The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as "unknown deaths," but were counted as CV deaths for the analysis of this endpoint.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions | 88 | 96 |
The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions | 88 | 96 |
The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme \>= 2x the ULN or CK \> 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions | 68 | 60 |
The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions | 72 | 62 |
Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions | 50 | 63 |
The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.
| participants | Combined RSG | Combined MET/SU |
|---|---|---|
| Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions | 53 | 64 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| All neoplasms/cancer (N/C) (benign/malignant) | 196 | 215 |
| Malignant (Mal.) N/C | 179 | 195 |
| Mal. N/C; excluding non-melanomatous skin cancers | 164 | 186 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
| participants | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|
| All neoplasms/cancer (N/C) (benign/malignant) | 60 | 51 |
| Malignant (Mal.) N/C | 59 | 51 |
| Mal. N/C; excluding non-melanomatous skin cancers | 55 | 46 |
The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Any genitourinary | 57 | 57 |
| Prostate | 22 | 22 |
| Renal | 12 | 9 |
| Uterine | 11 | 16 |
| Bladder | 8 | 5 |
| Vaginal/vulvar | 1 | 1 |
| Ovarian | 5 | 4 |
| Any gastrointestinal | 48 | 62 |
| Colon/rectal cancer | 22 | 30 |
| Colon | 14 | 21 |
| Gastric | 13 | 5 |
| Pancreatic | 5 | 16 |
| Liver | 4 | 5 |
| Gall bladder/biliary | 4 | 5 |
| Gastrointestinal; not specified | 0 | 1 |
| Any hematologic | 12 | 6 |
| Lung | 19 | 15 |
| Skin (non-melanomatous) | 19 | 13 |
| Skin (melanomatous) | 6 | 4 |
| Metastases | 12 | 18 |
| Breast | 12 | 23 |
| Head and neck | 4 | 7 |
| Neurologic | 3 | 3 |
| Endocrine | 3 | 6 |
| Not specified | 0 | 1 |
| Other | 0 | 3 |
The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
| participants | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|
| Any genitourinary | 18 | 8 |
| Prostate | 7 | 1 |
| Renal | 5 | 2 |
| Uterine | 4 | 4 |
| Bladder | 2 | 0 |
| Vaginal/vulvar | 0 | 1 |
| Ovarian | 0 | 0 |
| Any gastrointestinal | 17 | 19 |
| Colon/rectal cancer | 5 | 11 |
| Colon | 2 | 7 |
| Gastric | 5 | 1 |
| Pancreatic | 4 | 3 |
| Liver | 2 | 2 |
| Gall bladder/biliary | 1 | 1 |
| Gastrointestinal; not specified | 0 | 1 |
| Any hematologic | 6 | 1 |
| Lung | 6 | 6 |
| Skin (non-melanomatous) | 6 | 5 |
| Skin (melanomatous) | 3 | 2 |
| Metastases | 3 | 6 |
| Breast | 2 | 7 |
| Head and neck | 2 | 1 |
| Neurologic | 1 | 1 |
| Endocrine | 0 | 1 |
| Not specified | 0 | 0 |
| Other | 0 | 0 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Any cancer-related death | 59 | 72 |
| Any gastrointestinal event | 25 | 34 |
| Pancreatic | 4 | 12 |
| Colon/rectal | 6 | 11 |
| Gastric | 7 | 3 |
| Liver | 4 | 4 |
| Gall bladder/biliary | 4 | 3 |
| Gastrointestinal event; not specified | 0 | 1 |
| Any genitourinary event | 6 | 15 |
| Renal | 2 | 3 |
| Uterine | 1 | 5 |
| Prostate | 1 | 2 |
| Bladder | 1 | 3 |
| Ovarian | 1 | 2 |
| Lung | 13 | 11 |
| Any hematologic event | 4 | 0 |
| Skin (melanoma) | 3 | 0 |
| Skin (non-melanomatous) | 1 | 0 |
| Metastases | 2 | 4 |
| Breast | 2 | 3 |
| Head and neck | 1 | 2 |
| Any neurologic event | 2 | 2 |
| Endocrine | 1 | 0 |
| Not specified | 0 | 1 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
| participants | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|
| Any cancer-related death | 25 | 24 |
| Any gastrointestinal event | 10 | 14 |
| Pancreatic | 3 | 3 |
| Colon/rectal | 2 | 6 |
| Gastric | 2 | 1 |
| Liver | 2 | 2 |
| Gall bladder/biliary | 1 | 1 |
| Gastrointestinal event; not specified | 0 | 1 |
| Any genitourinary event | 2 | 0 |
| Renal | 1 | 0 |
| Uterine | 1 | 0 |
| Prostate | 0 | 0 |
| Bladder | 0 | 0 |
| Ovarian | 0 | 0 |
| Lung | 4 | 5 |
| Any hematologic event | 4 | 0 |
| Skin (melanoma) | 1 | 0 |
| Skin (non-melanomatous) | 1 | 0 |
| Metastases | 1 | 1 |
| Breast | 1 | 3 |
| Head and neck | 1 | 0 |
| Any neurologic event | 1 | 1 |
| Endocrine | 0 | 0 |
| Not specified | 0 | 0 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Overall, n=2220, 2227 | 238 | 151 |
| Male, n=1142, 1152 | 82 | 60 |
| Female, n=1078, 1075 | 156 | 91 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
| participants | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|
| Overall, n=1280, 1250 | 64 | 37 |
| Male, n=665, 635 | 25 | 11 |
| Female, n=615, 615 | 39 | 26 |
The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Any event | 81 | 57 |
| Upper limb | 41 | 17 |
| Distal lower limb | 24 | 16 |
| Femur/hip | 15 | 11 |
| Spinal | 7 | 9 |
| Pelvic | 0 | 3 |
| Other | 7 | 4 |
The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
| participants | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|
| Any event | 35 | 21 |
| Upper limb | 17 | 5 |
| Distal lower limb | 9 | 8 |
| Femur/hip | 6 | 4 |
| Spinal | 2 | 3 |
| Pelvic | 0 | 1 |
| Other | 2 | 1 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined | 0 | 0 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Any event, overall; n=2220, 2227 | 238 | 151 |
| Any event, male; n=1142, 1152 | 82 | 60 |
| Any event, female; n=1078, 1075 | 156 | 91 |
| Upper limb, any event, overall; n=2220, 2227 | 116 | 70 |
| Upper limb, any event, male; n=1142, 1152 | 32 | 22 |
| Upper limb, any event, female; n=1078, 1075 | 84 | 48 |
| Distal lower limb, any event, overall; n=2220, 222 | 88 | 40 |
| Distal lower limb, any event, male; n=1142, 1152 | 31 | 14 |
| Distal lower limb, any event, female; n=1078, 1075 | 57 | 26 |
| Femur/hip, any event, overall; n=2220, 2227 | 16 | 13 |
| Femur/hip, any event, male; n=1142, 1152 | 4 | 1 |
| Femur/hip, any event, female; n=1078, 1075 | 12 | 12 |
| Spinal, any event, overall; n=2220, 2227 | 18 | 14 |
| Spinal, any event, male; n=1142, 1152 | 7 | 9 |
| Spinal, any event, female; n=1078, 1075 | 11 | 5 |
| Pelvic, any event, overall; n=2220, 2227 | 0 | 5 |
| Pelvic, any event, male; n=1142, 1152 | 0 | 4 |
| Pelvic, any event, female; n=1078, 1075 | 0 | 1 |
| Unclassified, any event, overall; n=2220, 2227 | 1 | 0 |
| Unclassified, any event, male; n=1142, 1152 | 1 | 0 |
| Unclassified, any event, female; n=1078, 1075 | 0 | 0 |
| Other, any event, overall; n=2220, 2227 | 31 | 26 |
| Other, any event, male; n=1142, 1152 | 18 | 16 |
| Other, any event, female; n=1078, 1075 | 13 | 10 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
| participants | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|
| Any event, overall; n=1280, 1250 | 64 | 37 |
| Any event, male; n=665, 635 | 25 | 11 |
| Any event, female; n=615, 615 | 39 | 26 |
| Upper limb, any event, overall; n=1280, 1250 | 33 | 15 |
| Upper limb, any event, male; n=665, 635 | 10 | 3 |
| Upper limb, any event, female; n=615, 615 | 23 | 12 |
| Distal lower limb, any event, overall; n=1280,1250 | 18 | 13 |
| Distal lower limb, any event, male; n=665, 635 | 9 | 4 |
| Distal lower limb, any event, female; n=615, 615 | 9 | 9 |
| Femur/hip, any event, overall; n=1280, 1250 | 6 | 5 |
| Femur/hip, any event, male; n=665, 635 | 1 | 0 |
| Femur/hip, any event, female; n=615, 615 | 5 | 5 |
| Spinal, any event, overall; n=1280, 1250 | 4 | 5 |
| Spinal, any event, male; n=665, 635 | 1 | 4 |
| Spinal, any event, female; n=615, 615 | 3 | 1 |
| Pelvic, any event, overall; n=1280, 1250 | 0 | 1 |
| Pelvic, any event, male; n=665, 635 | 0 | 1 |
| Pelvic, any event, female; n=615, 615 | 0 | 0 |
| Unclassified, any event, overall; n=1280, 1250 | 1 | 0 |
| Unclassified, any event, male; n=665, 635 | 1 | 0 |
| Unclassified, any event, female; n=615, 615 | 0 | 0 |
| Other, any event, overall; n=1280, 1250 | 6 | 1 |
| Other, any event, male; n=665, 635 | 4 | 1 |
| Other, any event, female; n=615, 615 | 2 | 0 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Any event, overall, n=2220, 2227 | 31 | 31 |
| Any event, male, n=1142, 1152 | 10 | 13 |
| Any event, female, n=1078, 1075 | 21 | 18 |
| Hip, overall, n=2220, 2227 | 9 | 7 |
| Hip, male, n=1142, 1152 | 0 | 1 |
| Hip, female, n=1078, 1075 | 9 | 6 |
| Pelvis, overall, n=2220, 2227 | 0 | 5 |
| Pelvis, male, n=1142, 1152 | 0 | 4 |
| Pelvis, female, n=1078, 1075 | 0 | 1 |
| Upper leg, overall, n=2220, 2227 | 7 | 6 |
| Upper leg, male, n=1142, 1152 | 4 | 0 |
| Upper leg, female, n=1078, 1075 | 3 | 6 |
| Any vertebral event, overall, n=2220, 2227 | 16 | 13 |
| Any vertebral event, male, n=1142, 1152 | 6 | 8 |
| Any vertebral event, female, n=1078, 1075 | 10 | 5 |
| Lumbar spine, overall, n=2220, 2227 | 10 | 4 |
| Lumbar spine, male, n=1142, 1152 | 5 | 3 |
| Lumbar spine, female, n=1078, 1075 | 5 | 1 |
| Thoracic spine, overall, n=2220, 2227 | 5 | 8 |
| Thoracic spine, male, n=1142, 1152 | 1 | 4 |
| Thoracic spine, female, n=1078, 1075 | 4 | 4 |
| Cervical spine, overall, n=2220, 2227 | 1 | 1 |
| Cervical spine, male, n=1142, 1152 | 0 | 1 |
| Cervical spine, female, n=1078, 1075 | 1 | 0 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Any H/UA/FF event, overall, n=2220, 2227 | 86 | 46 |
| Any H/UA/FF event, male, n=1142, 1152 | 28 | 15 |
| Any H/UA/FF event, female, n=1078, 1075 | 58 | 31 |
| High morbidity fractures, overall, n=2220, 2227 | 5 | 1 |
| High morbidity fractures, male, n=1142, 1152 | 0 | 0 |
| High morbidity fractures, female, n=1078, 1075 | 5 | 1 |
| Non-high morbidity fractures, overall, n=2220, 222 | 15 | 4 |
| Non-high morbidity fractures, male, n=1142, 1152 | 2 | 3 |
| Non-high morbidity fractures, female, n=1078, 1075 | 13 | 1 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.
| participants | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Any event | 238 | 151 |
| Non-traumatic event | 113 | 55 |
| Traumatic event | 110 | 77 |
| Pathologic | 1 | 4 |
| Unknown | 20 | 19 |
| Data unavailable | 9 | 3 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."
| participants | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|
| Any event | 64 | 37 |
| Non-traumatic event, | 36 | 14 |
| Traumatic event | 24 | 17 |
| Pathologic | 1 | 2 |
| Unknown | 1 | 4 |
| Data unavailable | 3 | 1 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."
| bone fracture events | Combined RSG: Main Study and Observational Follow-up | Combined MET/SU: Main Study and Observational Follow-up |
|---|---|---|
| Number of bone fracture events | 299 | 174 |
| Unknown | 7 | 5 |
| Normal healing with standard management | 250 | 142 |
| Complication | 14 | 13 |
| Additional therapeutic measures required | 16 | 9 |
| Data unavailable | 12 | 5 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."
| bone fracture events | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|
| Number of bone fracture events | 70 | 41 |
| Unknown | 1 | 1 |
| Normal healing with standard management | 51 | 33 |
| Complication | 7 | 4 |
| Additional therapeutic measures required | 3 | 2 |
| Data unavailable | 8 | 1 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.
| participants | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|
| Any event | 99 | 76 |
| Ankle fracture | 6 | 3 |
| Prostate cancer | 7 | 1 |
| Lung neoplasm malignant | 4 | 4 |
| Breast cancer | 2 | 6 |
| Basal cell carcinoma | 4 | 3 |
| Pancreatic carcinoma | 4 | 3 |
| Colon cancer | 1 | 6 |
| Humerus fracture | 5 | 1 |
| Upper limb fracture | 5 | 1 |
| Malignant melanoma | 3 | 2 |
| Uterine cancer | 2 | 3 |
| Gastric cancer | 4 | 0 |
| Wrist fracture | 4 | 0 |
| Hip fracture | 3 | 1 |
| Radius fracture | 3 | 1 |
| Forearm fracture | 2 | 2 |
| Hepatic neoplasm malignant | 2 | 2 |
| Rectal cancer | 2 | 2 |
| Renal cancer | 2 | 2 |
| Foot fracture | 1 | 3 |
| Renal cell carcinoma | 3 | 0 |
| Femur fracture | 2 | 1 |
| Femoral neck fracture | 1 | 2 |
| Lumbar vertebral fracture | 1 | 2 |
| Metastases to bone | 1 | 2 |
| Metastases to liver | 1 | 2 |
| Bladder cancer | 2 | 0 |
| Fall | 2 | 0 |
| Metastases to central nervous system | 2 | 0 |
| Rib fracture | 2 | 0 |
| Squamous cell carcinoma | 2 | 0 |
| Acute myocardial infarction | 1 | 1 |
| Brain neoplasm | 1 | 1 |
| Gastric neoplasm | 1 | 1 |
| Metastases to lung | 1 | 1 |
| Patella fracture | 1 | 1 |
| Death | 0 | 2 |
| Abdominal pain | 1 | 0 |
| Acute myeloid leukaemia | 1 | 0 |
| Acute respiratory failure | 1 | 0 |
| Anaemia | 1 | 0 |
| Benign salivary gland neoplasm | 1 | 0 |
| Biliary colic | 1 | 0 |
| Biliary neoplasm | 1 | 0 |
| Bone neoplasm malignant | 1 | 0 |
| Bronchial carcinoma | 1 | 0 |
| Cardiac failure acute | 1 | 0 |
| Chest pain | 1 | 0 |
| Chronic lymphocytic leukaemia | 1 | 0 |
| Colon neoplasm | 1 | 0 |
| Contusion | 1 | 0 |
| Drowning | 1 | 0 |
| Dysplasia | 1 | 0 |
| Endometrial cancer stage I | 1 | 0 |
| Leukaemia | 1 | 0 |
| Lower limb fracture | 1 | 0 |
| Lung squamous cell carcinoma stage unspecified | 1 | 0 |
| Lymphoma | 1 | 0 |
| Malignant neoplasm of pleura | 1 | 0 |
| Metastases to skin | 1 | 0 |
| Metastases to testicle | 1 | 0 |
| Metastatic renal cell carcinoma | 1 | 0 |
| Oesophageal carcinoma | 1 | 0 |
| Osteoarthritis | 1 | 0 |
| Pancreatic necrosis | 1 | 0 |
| Rectal cancer stage II | 1 | 0 |
| Spinal fracture | 1 | 1 |
| T-cell lymphoma | 1 | 1 |
| Urinary tract infection | 1 | 1 |
| Uterine leiomyosarcoma | 1 | 0 |
| Biliary cancer metastatic | 0 | 1 |
| Cervix carcinoma | 0 | 1 |
| Chronic obstructive pulmonary disease | 0 | 1 |
| Comminuted fracture | 0 | 1 |
| Craniocerebral injury | 0 | 1 |
| Gastrointestinal neoplasm | 0 | 1 |
| Hepatic lesion | 0 | 1 |
| Joint dislocation | 0 | 1 |
| Laryngeal cancer | 0 | 1 |
| Lip neoplasm malignant stage unspecified | 0 | 1 |
| Lung neoplasm | 0 | 1 |
| Metastases to lymph nodes | 0 | 1 |
| Metastasis | 0 | 1 |
| Musculoskeletal chest pain | 0 | 1 |
| Myocardial infarction | 0 | 1 |
| Non-Hodgkin's lymphoma | 0 | 1 |
| Pubis fracture | 0 | 1 |
| Pulmonary embolism | 0 | 1 |
| Rectal cancer recurrent | 0 | 1 |
| Rectal neoplasm | 0 | 1 |
| Skin cancer | 0 | 1 |
| Skin ulcer | 0 | 1 |
| Small cell lung cancer stage unspecified | 0 | 1 |
| Sternal fracture | 0 | 1 |
| Subdural haemorrhage | 0 | 1 |
| Sudden death | 0 | 1 |
| Thoracic vertebral fracture | 0 | 1 |
| Thyroid cancer | 0 | 1 |
| Vulval cancer | 0 | 1 |
Collected over In the RECORD study (RS), SAEs were collected from BL through End of Study (up to 7.5 years); non-serious AEs were collected only for the randomized treatment period. SAEs were collected from the end of the RS through the end of OFU (up to 4.0 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RSG in Addition to Background MET | — | 424/1,117 (38%) | 1,117/1,117 (100%) |
| SU in Addition to Background MET | — | 428/1,105 (38.7%) | 1,105/1,105 (100%) |
| RSG in Addition to Background SU | — | 427/1,103 (38.7%) | 1,103/1,103 (100%) |
| MET in Addition to Background SU | — | 431/1,122 (38.4%) | 1,122/1,122 (100%) |
| Combined RSG: Observational Follow-up | — | 99/1,280 (7.7%) | 0/1,280 (0%) |
| Combined MET/SU: Observational Follow-up | — | 76/1,250 (6.1%) | 0/1,250 (0%) |
| Event | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|---|---|---|---|
| Myocardial InfarctionCardiac disorders | 25/1117 | 22/1105 | 29/1103 | 23/1122 | 0/1280 | 1/1250 |
| Cerebrovascular AccidentNervous system disorders | 18/1117 | 25/1105 | 21/1103 | 24/1122 | 0/1280 | 0/1250 |
| Cardiac Failure CongestiveCardiac disorders | 25/1117 | 18/1105 | 23/1103 | 13/1122 | 0/1280 | 0/1250 |
| Angina PectorisCardiac disorders | 23/1117 | 18/1105 | 23/1103 | 19/1122 | 0/1280 | 0/1250 |
| Angina UnstableCardiac disorders | 16/1117 | 20/1105 | 21/1103 | 18/1122 | 0/1280 | 0/1250 |
| PnuemoniaInfections and infestations | 21/1117 | 15/1105 | 11/1103 | 12/1122 | 0/1280 | 0/1250 |
| Atrial FibrillationCardiac disorders | 20/1117 | 15/1105 | 13/1103 | 14/1122 | 0/1280 | 0/1250 |
| Acute Myocardial InfarctionCardiac disorders | 12/1117 | 6/1105 | 11/1103 | 19/1122 | 1/1280 | 1/1250 |
| Diabetes MellitusMetabolism and nutrition disorders | 4/1117 | 5/1105 | 10/1103 | 17/1122 | 0/1280 | 0/1250 |
| Cardiac FailureCardiac disorders | 16/1117 | 1/1105 | 13/1103 | 8/1122 | 0/1280 | 0/1250 |
| Event | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU | Combined RSG: Observational Follow-up | Combined MET/SU: Observational Follow-up |
|---|---|---|---|---|---|---|
| HypertensionVascular disorders | 345/1117 | 372/1105 | 302/1103 | 319/1122 | 0/1280 | 0/1250 |
| HyperlipidaemiaMetabolism and nutrition disorders | 236/1117 | 144/1105 | 193/1103 | 120/1122 | 0/1280 | 0/1250 |
| NasopharyngitisInfections and infestations | 216/1117 | 202/1105 | 121/1103 | 122/1122 | 0/1280 | 0/1250 |
| HypoglycaemiaMetabolism and nutrition disorders | 51/1117 | 190/1105 | 162/1103 | 144/1122 | 0/1280 | 0/1250 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 121/1117 | 78/1105 | 155/1103 | 64/1122 | 0/1280 | 0/1250 |
| Back PainMusculoskeletal and connective tissue disorders | 153/1117 | 143/1105 | 95/1103 | 105/1122 | 0/1280 | 0/1250 |
| Oedema peripheralGeneral disorders | 144/1117 | 47/1105 | 133/1103 | 41/1122 | 0/1280 | 0/1250 |
| BronchitisInfections and infestations | 139/1117 | 128/1105 | 136/1103 | 122/1122 | 0/1280 | 0/1250 |
| DiarrhoeaGastrointestinal disorders | 60/1117 | 81/1105 | 44/1103 | 135/1122 | 0/1280 | 0/1250 |
| InfluenzaInfections and infestations | 110/1117 | 129/1105 | 106/1103 | 88/1122 | 0/1280 | 0/1250 |
| Age, Continuous(years) | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU | Total |
|---|---|---|---|---|---|
| Mean | 57.0 ± 8.02 | 57.2 ± 8.14 | 59.8 ± 8.26 | 59.7 ± 8.23 | 58.4 ± 8.27 |
| Sex: Female, Male(Participants) | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU | Total |
|---|---|---|---|---|---|
| Female | 516 | 521 | 562 | 554 | 2153 |
| Male | 601 | 584 | 541 | 568 | 2294 |
| Race/Ethnicity, Customized(participants) | RSG in Addition to Background MET | SU in Addition to Background MET | RSG in Addition to Background SU | MET in Addition to Background SU | Total |
|---|---|---|---|---|---|
| White | 1105 | 1087 | 1095 | 1112 | 4399 |
| Black | 3 | 6 | 2 | 3 | 14 |
| Oriental | 4 | 2 | 5 | 7 | 18 |
| Aboriginal | 1 | 0 | 0 | 0 | 1 |
| African | 1 | 0 | 0 | 0 | 1 |
| Asian | 1 | 2 | 1 | 0 | 4 |
| Egyptian | 1 | 0 | 0 | 0 | 1 |
| Gipsy | 1 | 0 | 0 | 0 | 1 |
| Indian | 0 | 1 | 0 | 0 | 1 |
| Maori | 0 | 1 | 0 | 0 | 1 |
| Middle East Hible | 0 | 1 | 0 | 0 | 1 |
| Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Polynesian | 0 | 1 | 0 | 0 | 1 |
| Sri Lankan | 0 | 2 | 0 | 0 | 2 |
| Tahitian | 0 | 1 | 0 | 0 | 1 |
Showing the first 100 of 447 sites across 25 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Apr 2001, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosiglitazone · Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea · Metformin